DHFR

P 218 is a novel DHFR inhibitor with antimalarial activity and antifolate effects and can be used to study Buruli ulcer.

Compound PDK0318, with CAS No. 645-33-0, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound PDK0318 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

DHFR-IN-16 (compound 8d) is an inhibitor of dihydrofolate reductase (DHFR) with an IC50 of 0.199 μM, and is valuable for anti-infection research.

DHFR-IN-18 (compound 19D) is a DHFR inhibitor utilized in leukemia-related research.

EGFR/DHFR-IN-1 (Compound 10e) is a dual inhibitor of EGFR and DHFR, with IC50 values of 0.151 µM and 0.541 µM, respectively. It induces cell cycle arrest in the G0-G1 and S phases.

DHFR-IN-21 (compound 5p) is an inhibitor of dihydrofolate reductase.

DHFR-IN-20 (Compound LA1) is an inhibitor of dihydrofolate reductase (DHFR) targeting the malignant strains of the malaria parasite. It exhibits inhibition constants (Kis) of 0.16 nM, 0.30 nM, and 6.6 nM for PfDHFR-WT, PfDHFR-QM, and HsDHFR, respectively. Additionally, DHFR-IN-20 demonstrates antimalarial activity, with IC50 values of 1.4 nM against parasites carrying the wild-type (TM4/8.2) PfDHFR enzyme and 1.6 μM against those with the quadruple mutation (V1/S)PfDHFR.

CB 3705 is a bio-active chemical.

EGFR/HER2/DHFR-IN-2 (Compound 4b) serves as an inhibitor for EGFR, HER2, and DHFR, with IC50 values of 0.248, 0.156, and 0.138 μM, respectively.

DHFR-IN-11 (compound 6b) is a DHFR inhibitor with demonstrated inhibitory efficacy against the M.

TH9028 TFA is an effective MTHFD2 inhibitor (IC50=11 nM) that suppresses proliferation in HL-60 cells, AML cells, and T-ALL Jurkat cells.

Anti-Dihydrofolate reductase Antibody (2V859) is an antibody targeting Dihydrofolate reductase. Anti-Dihydrofolate reductase Antibody (2V859) can be used in ELISA, WB, IHC, IP.

WR99210 hydrochloride is a potent inhibitor of Plasmodium falciparum dihydrofolate reductase (pfDHFR), which is a major malarial drug target.

Piritrexim isethionate, a fat-soluble DHFR inhibitor, shows efficacy in metastatic urothelial cancer with a 5-day oral regimen.

WR99210 (BRL 6231 free base) is a DHFR inhibitor with antiparasitic activity.

Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor.

DHFR-IN-3 (7-bromoquinazoline-2,4-diamine) is an active biochemical.

Key enzyme in folate metabolism.

Key enzyme in folate metabolism.

Key enzyme in folate metabolism.

Managlinat dialanetil, an orally available and potent inhibitor of fructose 1,6-bisphosphatase (FBPase) used in research 2 type diabetes.

10-Deazaaminopterin is a poly-gamma-glutamyl metabolite of the experimental anticancer drug, a folic acid antagonist, antineoplastic agent enzyme inhibitor.

Piritrexim (BW 301U) is an orally available fat-soluble dihydrofolate reductase inhibitor with pulmonary toxicity used in the study of uroepithelial carcinoma

Clociguanil has antimalarial activity.

Aditoprime (Aditoprim) is a selective bacterial DHFR inhibitor with strong nanomolar potency and broad-spectrum antibacterial activity.

DHFR-IN-5: potent, oral DHFR inhibitor, Ki 0.54 nM against mutant P. falciparum, anti-malarial.

Phototrexate, a photochromic Methotrexate analog, is a UVA-activated, reversible DHFR inhibitor with antifolate properties (IC50: 6 nM cis vs. 34 μM trans).

Methotrexate-gamma-aspartate has growth inhibitory effects. It is used in antibody-targeted liposomes.

DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with anti-tumour activity, inhibits EGFR and HER2 and can be used to study pancreatic cancer.